2025-07-05 - Analysis Report
Okay, here's an analysis of Eli Lilly and Co (LLY) based on the provided data. The report is structured with numbers, followed by simple analyses and is presented in English.

**Report on Eli Lilly and Co (LLY)**

**Company Overview:** Eli Lilly and Co is a global pharmaceutical company that develops and markets medicines across various therapeutic areas.

**1. Performance Relative to S&P 500 (VOO)**

*   **LLY Cumulative Return:** 251.35%
*   **VOO Cumulative Return:** 95.42%
*   **Absolute Outperformance:** 156.4% (LLY outperformed VOO by 156.4 percentage points)
*   **Relative Outperformance Position:** 54.2 (This indicates that LLY's outperformance relative to VOO is positioned at the 54.2nd percentile of its historical range)

**Analysis:**

LLY has significantly outperformed the S&P 500 (VOO) over the period examined. The relative outperformance position suggests LLY's current performance is above average compared to its historical trend, but not at an extreme high, indicating sustained strength rather than a speculative peak.

**Alpha, Beta Analysis**

| Year       | CAGR   | MDD    | Alpha   | Beta   | Cap(B)  |
|------------|--------|--------|---------|--------|---------|
| 2015-2017  | 10.0%  | 56.3%  | -19.0%  | 0.0    | 75.8    |
| 2016-2018  | 39.0%  | 58.6%  | 21.0%   | -0.1   | 103.9   |
| 2017-2019  | 50.0%  | 58.6%  | 20.0%   | 0.3    | 118.0   |
| 2018-2020  | 52.0%  | 58.6%  | 33.0%   | 0.1    | 151.6   |
| 2019-2021  | 106.0% | 60.6%  | 57.0%   | 0.2    | 248.0   |
| 2020-2022  | 98.0%  | 64.8%  | 96.0%   | 0.2    | 328.4   |
| 2021-2023  | 133.0% | 64.8%  | 115.0%  | 0.3    | 523.3   |
| 2022-2024  | 150.0% | 72.2%  | 124.0%  | 0.2    | 693.0   |
| 2023-2025  | 104.0% | 76.8%  | 57.0%   | 0.2    | 700.8   |

**Analysis:**

*   **CAGR:** Shows strong growth rates, especially in recent years (2019-2024).
*   **MDD:** Maximum Drawdown indicates significant potential downside risk.  Investors need to be aware of this volatility.
*   **Alpha:**  Consistently positive and high Alpha values indicate LLY's ability to generate returns independent of market movements, reflecting strong stock-picking or company-specific advantages.
*   **Beta:** Low Beta values suggest LLY is less sensitive to market fluctuations, contributing to its stable outperformance.
*   **Cap(B):**  Market capitalization has grown substantially, indicating increasing investor confidence.

**2. Recent Price Action**

*   **Current Price:** 780.67
*   **Previous Close:** 779.28
*   **Change:** 0.18 (Slight increase from previous close)
*   **5-day Moving Average:** 778.64
*   **20-day Moving Average:** 786.62
*   **60-day Moving Average:** 777.37

**Analysis:**

The current price is slightly above the 5-day and 60-day moving averages but below the 20-day moving average. This suggests a potential consolidation or short-term downward pressure after a recent rally. The small price increase from the previous day implies limited immediate momentum.

**3. Market Risk Indicators and Expected Return**

*   **Market Risk Indicator (MRI):** 0.33 (Low Risk)
*   **RSI:** 37.98 (Approaching oversold territory)
*   **PPO:** -0.1484 (Negative, indicating potential short-term weakness)
*   **Hybrid Signal:** cash_0%_Buy 80% of cash (3 shares - Caution - MRI:0.35)
*   **Recent (20-day) Relative Outperformance Change:** -3.3 (Decreasing, suggesting recent underperformance)
*   **Expected Return:** 136.1% (Long-term, relative to S&P 500)

**Analysis:**

The MRI indicates a low-risk environment. The RSI nearing oversold territory, combined with a negative PPO, could suggest a potential short-term buying opportunity, though caution is advised. The declining relative outperformance over the past 20 days indicates some short-term weakness. The very high expected return suggests analysts are optimistic about LLY's long-term prospects. The Hybrid Signal advises a partial buy.

**4. Recent News & Significant Events**

*   **July 5, 2025:** Major business developments, regulatory changes, or market events.
*   **July 4, 2025:** Analyst discussions on performance and outlook.
*   **July 2, 2025:** Notable stock volatility.
*   **July 1, 2025:** Market experts highlighting risks and opportunities.

**Analysis:**

Recent news suggests that LLY is experiencing significant activity, including market volatility and analyst discussions. Investors should monitor news and company announcements closely to stay informed about potential risks and opportunities.

**5. Recent Earnings Analysis**

| Date       | EPS  | Revenue       |
|------------|------|---------------|
| 2025-05-01 | 3.07 | 12.73 B$      |
| 2024-10-30 | 1.08 | 11.44 B$      |
| 2024-08-08 | 3.29 | 11.30 B$      |
| 2024-04-30 | 2.49 | 8.77 B$      |
| 2025-05-01 | 2.49 | 8.77 B$      |

**Analysis:**

Earnings per share (EPS) has been volatile but generally positive.  Revenue shows a generally increasing trend. The most recent data (2025-05-01) shows strong EPS and Revenue figures, indicating solid performance.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue   | Profit Margin |
|------------|-----------|---------------|
| 2025-03-31 | $12.73B   | 82.53%        |
| 2024-12-31 | $13.53B   | 82.24%        |
| 2024-09-30 | $11.44B   | 81.02%        |
| 2024-06-30 | $11.30B   | 80.80%        |
| 2024-03-31 | $8.77B    | 80.91%        |

**Capital and Profitability:**

| Quarter    | Equity    | ROE     |
|------------|-----------|---------|
| 2025-03-31 | $15.76B   | 17.50%  |
| 2024-12-31 | $14.19B   | 31.07%  |
| 2024-09-30 | $14.24B   | 6.81%   |
| 2024-06-30 | $13.56B   | 21.88%  |
| 2024-03-31 | $12.81B   | 17.51%  |

**Analysis:**

*   **Revenue:** Consistently increasing revenue indicates strong sales growth.
*   **Profit Margin:** Very high and stable profit margins suggest efficient operations and strong pricing power.
*   **Equity:** Growing equity reflects the company's increasing net worth.
*   **ROE:** Return on Equity is volatile, but generally high, indicating profitable use of shareholder investments.

**7. Overall Summary**

Eli Lilly and Co (LLY) demonstrates strong fundamentals and has significantly outperformed the S&P 500.  Its growth is supported by robust revenue growth, high profit margins, and strong expected returns.  While the recent stock volatility and decreasing relative outperformance warrant attention, the low-risk market environment and positive long-term outlook suggest a potentially attractive investment opportunity, especially for long-term investors.  Investors should remain vigilant and monitor news releases and earnings reports closely. The hybrid signal recommends a cautious partial buy.
